KDR and hepatocellular carcinoma: Phase 1 study (NCT02942329) of the VEGFR2 inhibitor apatinib plus anti-PD1 antibody SHR-1210 in patients with advanced hepatocellular carcinoma (HCC) has demonstrated manageable toxicity and encouraged clinical activity at recommended single-agent doses of both drugs (83).